Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M270Revenue (TTM) $M1.9Net Margin (%)-2,369.0Altman Z-Score3.4
Enterprise Value $M218EPS (TTM) $-1.8Operating Margin %-2,296.0Piotroski F-Score2
P/E(ttm)--Beneish M-Score1.0Pre-tax Margin (%)-2,369.0Higher ROA y-yY
Price/Book4.510-y EBITDA Growth Rate %--Quick Ratio8.4Cash flow > EarningsY
Price/Sales1225-y EBITDA Growth Rate %--Current Ratio8.4Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-48.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-63.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M25.0ROIC % (ttm)-6,194.7Gross Margin Increase y-yN

Gurus Latest Trades with OCUL

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OCUL is held by these investors:



OCUL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sawhney AmarpreetPresident and CEO, 10% Owner 2016-12-15Buy45,300$7.8519.62view
Sawhney AmarpreetPresident and CEO, 10% Owner 2016-06-09Buy10,000$6.740.15view
Sawhney AmarpreetPresident and CEO, 10% Owner 2015-11-17Buy10,000$8.2513.82view
Fortune JamesCOO 2015-09-15Sell9,470$17.16-45.28view
Sawhney AmarpreetPresident and CEO, 10% Owner 2015-09-14Buy15,000$16.5-43.09view
Versant Venture Capital III, L10% Owner 2015-06-15Sell320,000$22-57.32view
Warden Charles MDirector, 10% Owner 2015-06-15Sell320,000$22-57.32view
SVLSF IV, LLC10% Owner 2015-06-10Sell1,119,000$22-57.32view
Versant Venture Capital III, L10% Owner 2015-06-10Sell427,000$22-57.32view
Warden Charles MDirector, 10% Owner 2015-06-10Sell427,000$22-57.32view

Quarterly/Annual Reports about OCUL:

    News about OCUL:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 

    More From Other Websites
    ETFs with exposure to Ocular Therapeutix, Inc. : March 27, 2017 Mar 27 2017
    OCULAR THERAPEUTIX, INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 20 2017
    Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
    Positive Results Reported For Ocular Therapeutix Inc (OCUL) Dextenza Following Phase III Study Mar 17 2017
    OCULAR THERAPEUTIX, INC Financials Mar 16 2017
    Ocular's Dextenza Reports Positive Study Results Mar 16 2017
    After setback, Bedford eye care biotech has its sights set on FDA approval Mar 15 2017
    New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™... Mar 15 2017
    Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
    Edited Transcript of OCUL earnings conference call or presentation 10-Mar-17 1:30pm GMT Mar 10 2017
    Ocular Therapeutix Inc Earnings Call scheduled for 8:30 am ET today Mar 10 2017
    Ocular Therapeutix reports 4Q loss Mar 10 2017
    Ocular Therapeutix reports 4Q loss Mar 10 2017
    OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 10 2017
    Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results Mar 10 2017
    Q4 2016 Ocular Therapeutix Inc Earnings Release - Before Market Open Mar 10 2017
    Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial Results Mar 08 2017
    Biotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS) Feb 23 2017
    Blog Coverage Ocular Therapeutix Announced FDA Acceptance of NDA Resubmission for its Product for... Feb 23 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)